Septal Myectomy and Subvalvular Repair in Hypertrophic Cardiomyopathy, a Systematic Review and Pooled Analysis

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39076396

Authors

Ming-Yang Song

Xiang Wei

Chen-He Li

Rui Li

Affiliations

Soon will be listed here.

Abstract

Background: Some patients with hypertrophic obstructive cardiomyopathy (HOCM) still exhibit systolic anterior motion (SAM) and mitral regurgitation (MR) even after undergoing an isolated ventricular septectomy. Currently, there are disputes regarding whether to perform a mitral valve intervention and which type of operation is more effective.

Methods: By searching PubMed, Cochrane, Embase, Web of Science, FDA.gov, and ClinicalTrials.gov, as well as other resource databases, we obtained all articles published before December 2022 on ventricular septal myectomy combined with mitral valve intervention for hypertrophic cardiomyopathy. Demographic information and outcome variable data were extracted from 10 screened studies on ventricular septal resection combined with mitral valve repair. The risk of bias was assessed using methodological index for non-randomized studies (MINORS). Student's -test was used for comparisons of continuous variables, and the chi-square or Fisher's exact test was used for dichotomous variables. A total of 692 patients across 10 studies were analyzed.

Results: There were 5 (0.7%) deaths in the perioperative period. The average cardiopulmonary bypass time was 64.7 22.2 minutes, and the average follow-up time was 39.6 36.3 months. Compared with baseline levels, the left ventricular outflow tract gradient (83.6 32.2 mmHg vs. 11.0 7.8 mmHg, 0.01), maximum interventricular septal thickness (22.5 5.1 mm vs. 14.7 5.5 mm, 0.01), III/IV mitral regurgitation (351/692 vs. 17/675, 0.01), anterior mitral leaflet (AML)-annulus ratio (0.49 0.14 vs. 0.60 0.12, 0.01), tenting area (2.72 0.60 vs. 1.95 0.60 , 0.01), and SAM (181/194 vs. 11/215, 0.01) were significantly improved. 14 (2.1%) patients were in New York Heart Association functional class III/IV, which was significantly improved compared with the preoperative state (541/692 vs. 14/682, 0.01).

Conclusions: Ventricular septectomy combined with mitral valve repair can be a safe and effective treatment option for patients suffering from HOCM with SAM and severe MR.

References

Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C . Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol. 2015; 66(15):1687-96. DOI: 10.1016/j.jacc.2015.07.069. View

Tao J, Duan F, Long J, Meng Q, Zhang B, Zhu Z . The Role of the Submitral Apparatus in Hypertrophic Obstructive Cardiomyopathy. J Am Soc Echocardiogr. 2022; 36(2):133-145. DOI: 10.1016/j.echo.2022.09.018. View

Dorobantu L, Iosifescu T, Ticulescu R, Greavu M, Alexandrescu M, Dermengiu A . Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae-A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy. J Clin Med. 2022; 11(11). PMC: 9181673. DOI: 10.3390/jcm11113083. View

Hong J, Schaff H, Nishimura R, Abel M, Dearani J, Li Z . Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. J Am Coll Cardiol. 2016; 68(14):1497-504. DOI: 10.1016/j.jacc.2016.07.735. View

Raffa G, Romano G, Turrisi M, Morsolini M, Gentile G, Sciacca S . Pathoanatomic Findings and Treatment During Hypertrophic Obstructive Cardiomyopathy Surgery: The Role of Mitral Valve. Heart Lung Circ. 2018; 28(3):477-485. DOI: 10.1016/j.hlc.2018.02.006. View

Cape E, Simons D, Jimoh A, Weyman A, Yoganathan A, Levine R . Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies. J Am Coll Cardiol. 1989; 13(6):1438-48. DOI: 10.1016/0735-1097(89)90326-4. View

Rodriguez F, Langer F, Harrington K, Tibayan F, Zasio M, Liang D . Cutting second-order chords does not prevent acute ischemic mitral regurgitation. Circulation. 2004; 110(11 Suppl 1):II91-7. DOI: 10.1161/01.CIR.0000138396.24335.6a. View

Tang Y, Song Y, Duan F, Deng L, Ran J, Gao G . Extended myectomy for hypertrophic obstructive cardiomyopathy patients with midventricular obstruction. Eur J Cardiothorac Surg. 2018; 54(5):875-883. DOI: 10.1093/ejcts/ezy203. View

Ram E, Schwammenthal E, Kuperstein R, Jamal T, Nahum E, Sternik L . Secondary chordal resection with septal myectomy for treatment of symptomatic obstructive hypertrophic cardiomyopathy. Eur J Cardiothorac Surg. 2021; 60(3):699-707. DOI: 10.1093/ejcts/ezab116. View

10.

Zyrianov A, Spirito P, Abete R, Margonato D, Poggio D, Vaccari G . Impact of secondary mitral valve chordal cutting on valve geometry in obstructive hypertrophic cardiomyopathy with marked septal hypertrophy. Eur Heart J Cardiovasc Imaging. 2022; 24(5):678-686. DOI: 10.1093/ehjci/jeac179. View

11.

Balaram S, Tyrie L, Sherrid M, Afthinos J, Hillel Z, Winson G . Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. Ann Thorac Surg. 2008; 86(5):1539-44. DOI: 10.1016/j.athoracsur.2008.07.048. View

12.

Maron B, Rowin E, Maron M . Global Burden of Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018; 6(5):376-378. DOI: 10.1016/j.jchf.2018.03.004. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

14.

Wei L, Thibault D, Rankin J, Alkhouli M, Roberts H, Vemulapalli S . Contemporary Surgical Management of Hypertrophic Cardiomyopathy in the United States. Ann Thorac Surg. 2018; 107(2):460-466. DOI: 10.1016/j.athoracsur.2018.08.068. View

15.

Carvalho J, Schaff H, Nishimura R, Ommen S, Geske J, Lahr B . Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy?. J Thorac Cardiovasc Surg. 2021; 165(1):79-87.e1. DOI: 10.1016/j.jtcvs.2020.12.143. View

16.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Afanasyev A, Bogachev-Prokophiev A, Lenko E, Sharifulin R, Ovcharov M, Kozmin D . Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2018; 28(3):465-472. DOI: 10.1093/icvts/ivy269. View

19.

Krajcer Z, Leachman R, Cooley D, Coronado R . Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation. 1989; 80(3 Pt 1):I57-64. View

20.

Desai M, Bhonsale A, Smedira N, Naji P, Thamilarasan M, Lytle B . Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013; 128(3):209-16. DOI: 10.1161/CIRCULATIONAHA.112.000849. View